The Oncology Research Information Exchange Network, a partnership of academic cancer centers, has collected data from over 120,000 patients, and recently added four institutions.
Six NCI-designated cancer centers have agreed to pool data from their electronic medical record systems and cancer registries to accelerate discovery of targets and the development of biomarkers.
Mark Green, former director of Hollings Cancer Center at the Medical University of South Carolina and the University of California, San Diego, Moores Cancer Center, died Feb. 23, at the age of 70.
FDA approved Zarxio, making Sandoz's granulocyte-colony stimulating factor the first biosimilar product to enter the U.S. market.
After months of training, hundreds of hours spent in a high-altitude sleep tent, and almost a week spent ascending the mountain, our climbing group was destined to have only 12 minutes at Mt. Kilimanjaro's summit. However, that was enough to pay tribute to the 200,000 heroes who have participated in more than a half-century of SWOG cancer clinical trials.
Citing a dramatic improvement in overall survival in second-line squamous non-small cell lung cancer, FDA rapidly approved the Bristol-Myers Squibb drug Opdivo (nivolumab).
The National Cancer Institute Harold Varmus will leave on March 31 is leaner, cleaner, and more focused than it was on July 12, 2010, the day he became its 14th director.
NCI Director Harold Varmus announced that he will be stepping down at the end of this month.
Meir Wetzler, 60, chief of the Leukemia Section at the Roswell Park Cancer Institute, died Feb. 23, nearly two weeks after a skiing accident in Denver, Colo.
The Patient-Centered Outcomes Research Institute approved awards totaling more than $64 million to fund five large patient-centered comparative effectiveness research studies concentrating on cancer, back pain and stroke.
